Prostate Cancer - Results from #1280

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. March 5, 2024

Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer. March 4, 2024

Racial disparities in diagnosis and treatment of depression Associated with androgen deprivation therapy for prostate cancer. March 4, 2024

High dimensional analyses reveal IL-15 enhances activation of Sipuleucel-T lymphocyte subsets and reverses immunoresistance. March 4, 2024

A Phase I Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy. March 4, 2024

Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial. March 4, 2024

Genomic evolution shapes prostate cancer disease type. March 4, 2024

Healthy dietary patterns and risk of prostate cancer in men at high genetic risk. March 4, 2024

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. March 4, 2024

Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. March 4, 2024

Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby March 1, 2024

The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. March 1, 2024

CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. March 1, 2024

Evaluation of Survival Outcomes Among Black and White Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. March 1, 2024

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. March 1, 2024

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. March 1, 2024

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. March 1, 2024

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. March 1, 2024

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. March 1, 2024

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. March 1, 2024

Page 65 of 1436